Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
Recruiting now Phase 2 NCT07486960
Run by Merck Sharp & Dohme LLC · for 18 to 80 · All sexes
What this study is about
Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Who can join (things the study team will check)
✅ You may be able to join if…
- Has a clinical diagnosis of PsA and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening, with symptom onset ≥6 months before Screening.
- Has a diagnosis of active plaque psoriasis or documented history of plaque psoriasis.
- Has history of biologic disease-modifying antirheumatic drug (bDMARD)-naïve or bDMARD-inadequate response/intolerant.
🚫 You may not be able to join if…
- Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than PsA (such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, myositis, etc), or any other conditions that may, in the judgment of the investigator, interfere with the assessment of PsA.
- Has a skin condition diagnosis, other than psoriasis that may, in the judgment of the investigator, interfere with the assessment of psoriasis.
- Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for <5 years before Randomization.
- Has any active infection.
- Has known allergies, hypersensitivity, or intolerance to tulisokibart of its excipients.
Where this trial is running
- Arizona Arthritis & Rheumatology Associates, P.C. ( Site 5117), Sun City, Arizona, United States
- Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 5120), Tucson, Arizona, United States
- Medvin Clinical Research - Riverside ( Site 5115), Riverside, California, United States
- Cohen Medical Centers ( Site 5111), Thousand Oaks, California, United States
- Medvin Clinical Research - Tujunga ( Site 5113), Tujunga, California, United States
- Arthritis and Rheumatic Disease Specialties ( Site 5105), Aventura, Florida, United States
- International Center for Research ( Site 5124), Tampa, Florida, United States
- St. Luke's Clinic - Rheumatology - Boise ( Site 5109), Boise, Idaho, United States
- Arthritis and Rheumatism Associates - Rockville ( Site 5127), Rockville, Maryland, United States
- Kansas City Physician Partners ( Site 5119), Kansas City, Missouri, United States
- Physician Research Collaboration, LLC ( Site 5102), Lincoln, Nebraska, United States
- Joint and Muscle Research Institute ( Site 5108), Charlotte, North Carolina, United States
+ 34 more sites.
Who to contact
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07486960.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.